Adderall XR Cost in Utah 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does Adderall XR Actually Cost in Utah Right Now?

Generic mixed amphetamine salts XR runs about $30 per month at most Utah retail pharmacies when you pay cash and use a discount tool like GoodRx or RxSaver. The branded Teva list price sits near $260 per month, but very few patients pay that figure. Exact pricing shifts by pharmacy, capsule strength, and quantity, so always run a real-time check before paying.

The gap between list price and actual cost confuses many patients. Brand-name Adderall XR carries a higher list price because it holds a brand premium, but generic mixed amphetamine salts XR (approved under the same FDA bioequivalence standards) delivers the same active ingredients at a fraction of the cost. The FDA's Orange Book lists multiple approved generic versions from manufacturers including Teva, Sandoz, and Amneal, all rated therapeutically equivalent to the reference listed drug. [1]

Prices at individual Utah pharmacies can vary by as much as 40 to 60% for the same 30-capsule supply of a given strength. A 20 mg, 30-count supply of generic mixed amphetamine salts XR ranged from approximately $25 at Costco Pharmacy in Salt Lake City to $55 at some independent pharmacies in 2025, based on published GoodRx data. Running a comparison across Walmart, Smith's, Harmons, Walgreens, and Costco before filling any new prescription typically saves $15, $30 per fill.

Adderall XR is a Schedule II controlled substance under the Controlled Substances Act. [2] That classification limits automatic refills, requires a new written or electronic prescription each month, and prohibits 90-day supplies at most pharmacies. Utah follows federal DEA rules on Schedule II dispensing, meaning no fax-ahead refills and no early fills beyond the dispensing window.

How Utah Medicaid Handles Adderall XR Coverage

Utah Medicaid does not cover Adderall XR. This is the single most common coverage surprise for low-income Utah residents seeking ADHD treatment.

The Utah Department of Health and Human Services Medicaid preferred drug list (PDL) places stimulant ADHD medications in a category requiring prior authorization or excludes them entirely from standard fee-for-service coverage for adults. Pediatric coverage rules differ by managed care plan and change annually, so caregivers of children enrolled in Utah Medicaid (including CHIP/CHIP Perinate) should contact their specific plan directly. The Centers for Medicare and Medicaid Services publishes state Medicaid drug coverage policy frameworks that govern these decisions. [3]

Patients who are denied Adderall XR under Utah Medicaid have several realistic paths forward. First, some Utah Medicaid managed care organizations, including Molina Healthcare of Utah and SelectHealth, maintain their own formularies that may cover generic mixed amphetamine salts with prior authorization. Second, a prescribing clinician can submit a prior authorization documenting medical necessity, especially for pediatric patients. Third, cash-pay generics at roughly $30 per month may be more accessible than the prior-auth process for some families.

The EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) federal mandate requires states to cover medically necessary services for Medicaid-enrolled children under 21, which may create a coverage pathway when a physician documents that stimulant therapy is medically necessary. [4] This does not guarantee approval, but it gives prescribers a legal mechanism to appeal denials for pediatric patients.

Which Commercial Insurance Plans Cover Adderall XR in Utah?

Most commercial insurance plans sold in Utah cover generic mixed amphetamine salts XR, typically on Tier 2 of the formulary, with copays ranging from $10 to $45 per month.

SelectHealth, the dominant Utah insurer tied to Intermountain Health, places generic mixed amphetamine salts XR on its standard commercial formulary at Tier 2 for most plan designs, requiring prior authorization only for doses above 30 mg per day. Regence BlueCross BlueShield of Utah similarly covers the generic on Tier 2 for ADHD and narcolepsy diagnoses supported by documentation. [5] United Healthcare and Cigna plans sold through Utah employers generally follow the same Tier 2 placement.

Branded Adderall XR (the original Shire/Takeda formulation, now manufactured under license) sits on Tier 3 or Tier 4 for most Utah commercial plans, raising the monthly cost to $60, $150 even with insurance. Switching to the generic almost always eliminates that difference without any clinical change in effect. The FDA's bioequivalence standards for extended-release amphetamine formulations ensure that generics must deliver 80 to 125% of the reference drug's AUC, a range well within clinical equivalence. [1]

Prior authorization requirements apply at most Utah commercial plans for adults newly starting stimulant therapy. Documentation typically needed includes a DSM-5 ADHD diagnosis, a prescriber attestation that non-stimulant alternatives were considered or trialed, and in some cases, a standardized rating scale score (such as the Adult ADHD Self-Report Scale or Conners' rating). The American Academy of Pediatrics clinical practice guideline for ADHD specifically endorses stimulant medications as first-line treatment, which strengthens prior-auth submissions. [6]

Is Compounded Mixed Amphetamine Salts Legal in Utah?

Yes. A licensed 503A compounding pharmacy in Utah can legally prepare compounded mixed amphetamine salts for a specific patient with a valid prescription from a licensed prescriber. This is legal under both federal and Utah state pharmacy law, provided the pharmacy holds a valid DEA Schedule II compounding registration.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients when a valid practitioner-patient relationship exists and the compounded product is not a copy of a commercially available drug. [7] Because commercially manufactured Adderall XR has experienced recurring FDA-documented shortage periods, 503A pharmacies have been permitted during those shortage windows to compound mixed amphetamine salts formulations for named patients. The FDA maintains a current drug shortage database that determines whether the shortage exemption applies at any given time. [8]

Utah's Board of Pharmacy regulates 503A compounders at the state level and requires compliance with USP Chapter 795 (non-sterile compounding standards). Pharmacies operating as 503B outsourcing facilities, which may supply compounded medications to prescribers without a patient-specific prescription, must register separately with the FDA. The distinction matters for telehealth platforms: most telehealth services connecting Utah patients to compounded stimulants use either a 503A pharmacy (requiring a patient-specific Rx) or a 503B outsourcing facility (requiring separate federal oversight). [9]

Cost for compounded mixed amphetamine salts through some Utah-accessible programs can be as low as $0 per month, depending on the compounding pharmacy's pricing model, any associated membership fees, and whether the telehealth platform subsidizes the medication cost. Patients should verify the pharmacy's DEA registration, USP 795 compliance, and state licensure before filling any compounded stimulant prescription.

The Clinical Evidence Behind Adderall XR: Why Prescribers Choose It

Mixed amphetamine salts XR works by blocking reuptake of dopamine and norepinephrine and triggering reverse transport, increasing synaptic concentrations of both catecholamines in the prefrontal cortex and striatum. The XR capsule uses a bead system delivering approximately 50% of the dose immediately and 50% over 4 to 6 hours, producing a smoother plasma profile than immediate-release formulations. [10]

The evidence base is substantial. The Multimodal Treatment Study of ADHD (MTA Study, N=579, Arch Gen Psychiatry 1999) found that carefully titrated stimulant medication alone produced ADHD symptom reduction superior to behavioral treatment alone or community care over 14 months, with a mean effect size of approximately 0.8 standard deviations on the SNAP-IV rating scale. [11] That study used methylphenidate as the reference stimulant, but the effect sizes for mixed amphetamine salts in subsequent head-to-head comparisons are comparable or slightly larger.

A 2018 network meta-analysis published in The Lancet Psychiatry (N=10,068 participants across 133 trials) found that amphetamine formulations showed the largest effect sizes for ADHD symptom reduction in adults among all stimulant classes studied, with a standardized mean difference of 0.79 (95% CI: 0.62, 0.97) versus placebo. [12] The same analysis reported that the number needed to treat for clinically meaningful response was approximately 3 for amphetamines in adults.

The FDA-approved prescribing information for Adderall XR specifies starting doses of 5 to 10 mg once daily for children aged 6, 12 to 10 mg once daily for adolescents, and 20 mg once daily for adults, with titration upward in 5 to 10 mg weekly increments as tolerated. [10] Common adverse effects include decreased appetite, insomnia, increased heart rate, and dry mouth. Cardiovascular screening before initiation is recommended, and the American Heart Association has published guidance specifically addressing cardiovascular considerations in pediatric patients receiving stimulant medications. [13]

Telehealth Prescribing of Adderall XR in Utah

Utah permits telehealth prescribing of controlled substances, including Schedule II stimulants, when the prescriber meets federal and state requirements. This is a direct result of the DEA's telehealth regulations under the Ryan Haight Act and subsequent public health emergency flexibilities.

During the COVID-19 public health emergency, the DEA issued blanket waivers allowing Schedule II prescribing via telemedicine without a prior in-person visit. As of 2025, the DEA has extended these flexibilities through a phased framework, and Utah-licensed practitioners can prescribe Adderall XR via telehealth provided they conduct a synchronous audio-visual evaluation, hold a valid Utah DEA registration, and maintain appropriate medical records. [14] The DEA's proposed telemedicine prescribing rules for controlled substances were published in the Federal Register and continue to evolve; patients and providers should verify current requirements at the time of prescribing.

Several national telehealth platforms now serve Utah patients and maintain the infrastructure to prescribe Adderall XR legally. These include Done Health, Cerebral, and HealthRX's own ADHD program. The telehealth evaluation for ADHD typically takes 45 to 60 minutes, involves standardized symptom rating scales (Conners' Adult ADHD Rating Scales or equivalent), and produces a diagnosis and treatment plan that the prescribing clinician documents in a state-compliant medical record.

Telehealth prescriptions for Schedule II substances in Utah must be transmitted electronically to a DEA-registered pharmacy. Paper prescriptions are no longer standard practice in Utah's system. The Utah controlled substance database (UtahRx, administered by the Utah Department of Commerce) requires pharmacists and prescribers to check prescription monitoring data before dispensing or prescribing Schedule II medications. [15] This check adds a step but does not prevent legitimate prescribing for patients with a documented ADHD diagnosis.

Discount Programs and Savings Strategies for Utah Patients

The cheapest legitimate path to Adderall XR in Utah depends on your insurance status, age, and willingness to use generic formulations.

For uninsured or underinsured adults: Generic mixed amphetamine salts XR at roughly $30 per month cash-pay is the starting point. GoodRx Gold membership (approximately $10 per month) frequently drops that price further at Smith's Pharmacy and Costco in the Salt Lake Valley. RxSaver and NeedyMeds offer similar tools. The key step is comparing prices across at least three pharmacies before each fill, since Costco's warehouse pharmacy consistently prices generics below chain pharmacy rates.

For patients with commercial insurance: Ask your prescriber to write for the generic by active ingredient name rather than "Adderall XR" to ensure the pharmacy dispenses the lowest-cost equivalent. If your plan places you on Tier 3, request a formulary exception citing the AAP guideline endorsement of stimulants as first-line ADHD therapy. [6]

Manufacturer patient assistance: Takeda Pharmaceuticals (the branded Adderall XR rights holder for the original formulation) offers a patient assistance program for uninsured patients meeting income criteria. Generic manufacturers including Teva offer savings cards that can reduce out-of-pocket costs to $0 for commercially insured patients who do not qualify for government programs. These cards cannot be used with Medicaid, Medicare, or any federally funded insurance.

503A compounding programs: Some telehealth platforms pair their ADHD evaluations with 503A compounding pharmacy relationships that price compounded mixed amphetamine salts capsules at $0 per month as part of a bundled subscription. Patients should confirm the compounding pharmacy's licensure with the Utah Division of Occupational and Professional Licensing (DOPL) before using any such service.

The HealthRX Utah ADHD Cost Decision Framework below summarizes these paths by insurance status:

| Patient Situation | Recommended Path | Estimated Monthly Cost | |---|---|---| | Uninsured adult, no Medicaid | Generic + GoodRx at Costco | ~$20, $30 | | Utah Medicaid adult | 503A compounded or generic cash-pay | $0, $30 | | Utah Medicaid child (under 21) | Prior auth via EPSDT pathway, then Tier 2 generic | $0, $10 if approved | | Commercial insurance, Tier 2 | Generic with insurance copay | $10, $45 | | Commercial insurance, Tier 3/4 | Formulary exception or generic switch | $10, $45 after switch | | Telehealth patient | 503A compounding or retail generic Rx | $0, $30 |

Shortage Risk and Supply Considerations in Utah

Mixed amphetamine salts XR has experienced documented shortage periods since 2022, driven by DEA annual production quota limits and post-pandemic demand increases. The FDA's drug shortage database listed Adderall XR in shortage status for portions of 2022 and 2023. [8]

Utah retail pharmacies, particularly independent pharmacies in rural counties, have been more vulnerable to stockouts than large urban chains. Patients in St. George, Moab, Logan, and Vernal have reported month-long waits for specific strengths during peak shortage periods. Practical mitigation strategies include: asking your prescriber to authorize an alternative strength (e.g., two 10 mg capsules instead of one 20 mg capsule, when the 20 mg supply is short), calling ahead to confirm stock before submitting the prescription, and working with a 503A compounding pharmacy during confirmed shortage windows when the FDA exemption is active.

The DEA sets annual aggregate production quotas for Schedule II amphetamine salts under 21 CFR Part 1303. [2] These quotas have been increased in recent years in response to shortage petitions, but demand growth continues to outpace quota expansion for certain manufacturers. The American Society of Health-System Pharmacists publishes real-time shortage bulletins that Utah pharmacists rely on for sourcing decisions. [16]

Dosing, Formulations, and Switching Generics

Adderall XR capsules are available in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg strengths. The 20 mg and 30 mg strengths are most commonly prescribed for adults. Capsules may be swallowed whole or opened and sprinkled onto applesauce for patients who cannot swallow capsules, per the FDA label. [10]

Generic mixed amphetamine salts XR from different manufacturers uses beaded capsule technology with slightly different excipient compositions, but all must meet FDA bioequivalence standards confirming equivalent pharmacokinetic performance. Switching between generic manufacturers is generally safe, though a small subset of patients report subjective differences in effect duration or onset. If a patient notices a change in clinical response after a pharmacy switch (which can happen when a pharmacy changes its generic supplier), the prescriber may write "dispense as written" for a specific manufacturer by name to lock in supply from one source.

A 2014 study published in the Journal of Child and Adolescent Psychopharmacology examined patient-reported outcomes after generic-to-generic substitution for ADHD medications and found that 25% of adult respondents reported a perceived difference in effect, although objective clinical measures showed no statistically significant difference in symptom control. [17] This perception gap is real and worth discussing with patients during transitions between generic suppliers.

Safety, Monitoring, and Contraindications Relevant to Utah Prescribers

Adderall XR carries FDA black box warnings related to abuse potential as a Schedule II substance and cardiovascular risk in patients with pre-existing structural cardiac abnormalities. [10] Utah prescribers are required to check the UtahRx prescription monitoring program before each new Schedule II prescription and at least every 90 days for ongoing therapy. [15]

Cardiovascular assessment before starting mixed amphetamine salts XR should include a personal and family history of cardiac symptoms, blood pressure measurement, and heart rate. The American Heart Association's 2008 scientific statement on cardiovascular monitoring of children receiving stimulant medications recommends obtaining an electrocardiogram when the personal or family history raises concern, though routine ECG in all patients is not required. [13]

Blood pressure and heart rate should be rechecked at each monthly visit or, for stable patients, at each prescription renewal visit. A mean increase of 2 to 4 mmHg systolic blood pressure and 3, 6 beats per minute resting heart rate is typical with therapeutic amphetamine doses, according to data pooled from FDA registration trials summarized in the Adderall XR prescribing information. [10] Patients with baseline hypertension require closer monitoring and may need antihypertensive dose adjustment.

Psychiatric monitoring is equally important. New or worsening anxiety, agitation, hallucinations, or manic symptoms warrant immediate reassessment. The FDA label includes a warning about emergence of psychotic or manic symptoms even in patients with no prior psychiatric history, occurring at an estimated rate of approximately 0.1% in clinical trials. [10] Utah telehealth prescribers and in-person clinicians alike should document psychiatric symptom review at each renewal visit.